Transfusion of an irradiated product is indicated in all of the following conditions except:

Transfusion of an irradiated product is indicated in all of the following conditions except:

• A. Exchange transfusion
• B. Bone marrow transplant
• C. Severe combined immunodeficiency syndrome (SCIDS)
• D. Warm autoimmune hemolytic anemia (WAIHA)

Answer: (D)

The rationale for choosing the situation involving warm autoimmune hemolytic anemia (WAIHA) as the exception to the requirement for irradiated blood products pertains to the nature of the underlying immunological condition. Irradiation of blood products is primarily done to prevent transfusion-associated graft-versus-host disease (TA-GvHD) in patients with compromised immune systems. Conditions like bone marrow transplant, severe combined immunodeficiency syndrome (SCIDS), and situations requiring exchange transfusion usually involve patients who are significantly immunocompromised. For these patients, receiving non-irradiated blood products could risk the development of TA-GvHD, as their immune systems cannot effectively eradicate new donor lymphocytes introduced through transfusion. In contrast, patients with WAIHA typically do not have the same level of immune suppression as those in the other scenarios. Their immune response may be abnormal, attacking their own red blood cells, but they generally retain sufficient immune function to handle non-irradiated blood without the same risk for TA-GvHD. Thus, while irradiated blood is beneficial for many immunocompromised patients, it is not routinely required for patients with WAIHA. This is why WAIHA stands out as an exception in this

The rationale for choosing the situation involving warm autoimmune hemolytic anemia (WAIHA) as the exception to the requirement for irradiated blood products pertains to the nature of the underlying immunological condition.

Irradiation of blood products is primarily done to prevent transfusion-associated graft-versus-host disease (TA-GvHD) in patients with compromised immune systems. Conditions like bone marrow transplant, severe combined immunodeficiency syndrome (SCIDS), and situations requiring exchange transfusion usually involve patients who are significantly immunocompromised. For these patients, receiving non-irradiated blood products could risk the development of TA-GvHD, as their immune systems cannot effectively eradicate new donor lymphocytes introduced through transfusion.

In contrast, patients with WAIHA typically do not have the same level of immune suppression as those in the other scenarios. Their immune response may be abnormal, attacking their own red blood cells, but they generally retain sufficient immune function to handle non-irradiated blood without the same risk for TA-GvHD. Thus, while irradiated blood is beneficial for many immunocompromised patients, it is not routinely required for patients with WAIHA. This is why WAIHA stands out as an exception in this